potential for its development and
commercialization and clinical development, regulatory processes, and
commercialization efforts related to Nexavar. These statements are subject
to risks and uncertainties that could cause actual results and events to
differ materially from those anticipated. Reference should be made to
Onyx's Annual Report on Form 10-K for the year ended December 31, 2007,
filed with the Securities and Exchange Commission under the heading "Risk
Factors" and Onyx's Quarterly Reports on Form 10-Q for a more detailed
description of such factors. Readers are cautioned not to place undue
reliance on forward-looking statements that speak only as of the date of
this release. Onyx undertakes no obligation to update publicly any
forward-looking statements to reflect new information, events, or
circumstances after the date of this release except as required by law.
Nexavar(R) (sorafenib) tablets is a registered trademark of Bayer
HealthCare Pharmaceuticals, Inc.